insitro is an exciting startup company that aims to take a new approach to drug development: one with big data and machine learning at its core. We plan to build on the ground-breaking innovations that have occurred in life sciences to develop large data sets that are designed from the start to allow machine learning to address fundamental bottlenecks in the drug development process. Our goal is to cure more people, sooner, and at a much lower cost. We are fortunate to have the strong support from the top investors in both biotech and tech: ARCH Ventures, Foresite Capital, A16Z, GV, and Third Rock Ventures. We are building a remarkable team that embodies a new type of culture, one based on a true partnership between scientists, engineers, and data scientists. Together we are working to define the problems, design experiments, analyze the data, and derive the insights that will lead us to new therapeutics. Join us, and help make a difference to patients!
Powerful machine learning requires powerful data. Our data pipelines and automation infrastructure allow us to go beyond artisanal chemistry and biology, and rapidly generate massive amounts of high-quality data. This scale allows us to span much more of the diversity of human disease and potential therapies.
With massive amounts of high quality data, we then develop and deploy a variety of leading-edge machine learning methods. As witnessed in other industries, machine learning can make sense of vast amounts of high-dimensional data that are beyond human ability to interpret. Our machine learning models allow us to differentiate between cell states at much finer granularity and predict disease-relevant clinical traits.